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Abstract
John Finberg is a professor of pharmacology at the Faculty of Medicine, Technion – Israel Institute
of Technology, home of Israel's two Nobel laureates. He and his colleague Prof. Moussa Youdim
were instrumental in the early clinical development of the anti-Parkinson drug rasagiline, which
gained UK- and EU-marketing authorization in 2005 and US FDA approval in 2006. In our interview,
Finberg reflects on his clinical research to develop rasagiline as a commercial drug and its proposed
pharmacological mechanisms of action. Moreover, he elucidates the current state of anti-Parkinson
drug discovery and offers direction for future research.
What focus have you taken in the field of 
pharmacology, and what interesting results have 
you seen?
Since joining the Faculty of Medicine at the Technion,
Haifa, most of my research has been connected with cate-
cholamines, mainly studies on the mechanism of the
action of antidepressants, and on drugs for the treatment
of Parkinson's disease. My major interest has been on the
pharmacology of MAO inhibitors. These are fascinating
compounds, since they can be used to cause irreversible
and highly selective inactivation of one of the isoforms,
i.e., MAO-A or MAO-B. Because they cause "laser-like"
selective enzyme inactivation, one can use them to study
not only the pharmacological effects of the drugs, but also
the physiological role of these important enzymes. Inhib-
itors of the A form of the enzyme are effective antidepres-
sants, and I was interested to understand the way in which
inhibition of this enzyme affects neuronal noradrenaline
release. Remember that, like other neurotransmitters,
noradrenaline is released physiologically by exocytosis,
and cleared from the extracellular space mainly by
reuptake, so the effects of MAO inhibition are not easily
predictable. Using in vivo micro dialysis, I was able to
show that long-term administration of MAO-A inhibitors
does increase CNS extracellular noradrenaline levels [1],
by reduction in net neuronal uptake, and a similar effect
occurs in the periphery.
I was also interested in the pharmacology of MAO-B
inhibitors. My colleague Professor Moussa Youdim
observed selective MAO-B inhibitory property in a com-
pound now known as rasagiline. The only other selective
MAO-B inhibitor available for clinical use before the
advent of rasagiline was selegiline, a compound based on
the amphetamine structure. The important questions at
the start of this project were (a) is the nonpotentiation of
tyramine by selegiline due to its amphetamine-like prop-
erties, and (b) will rasagiline increase striatal dopamine
levels, in spite of its lack of amphetamine-like effect? With
graduate students Meir Tenne and Itschak Lamensdorf, we
showed that nonpotentiation of tyramine is a general
property of MAO-B inhibitors (because MAO-A is the
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enzyme isoform expressed in sympathetic neurons). We
also showed, using in vivo micro dialysis, that both rasag-
iline and selegiline increased extracellular dopamine lev-
els in rats, provided they are given chronically [2,3]. These
studies paved the way for the clinical development of ras-
agiline for treatment of Parkinson's disease. Subsequently,
with colleague Dr. John Commissiong (NIH) and gradu-
ate student Daphna Bonneh-Barkay, we observed the neu-
roprotective properties of rasagiline [4,5].
What is the proposed mechanism for the anti-
Parkinson activity of rasagiline?
Rasagiline, like selegiline, has anti-parkinsonian activity
when used in monotherapy in the early stages of the dis-
ease. It has always been difficult to understand how selec-
tive inhibition of MAO-B causes this apparent
dopaminergic response, since MAO-A is thought to be the
major form responsible for dopamine breakdown in the
intact striatum [see reference [6] for a detailed discussion].
One explanation for the effectiveness of MAO-B inhibi-
tors to increase dopamine release could be the accumula-
tion of endogenous β-phenylethylamine. This interesting
dopamine-releasing "trace amine" is normally very rap-
idly metabolized by MAO-B, but its concentration
increases markedly with inhibition of the enzyme. In
addition, primate species express a much higher propor-
tion of MAO-B to MAO-A activity in the brain than do
rodents. Currently, I am studying how MAO-B inhibitors
affect the metabolism of dopamine, both that released
endogenously, and also from exogenous L-DOPA, and
how this process changes with progressive loss of
dopaminergic neurons, and increasing metabolism in
glia.
Where does rasagiline fit into the current scope 
of Parkinson's disease therapy?
Rasagiline is effective in monotherapy in the early stage of
the disease, and can be used instead of dopaminergic ago-
nists. In the more advanced stages of the disease, it is given
together with L-DOPA, when it produces a significant
increase in the "on-time" per day, and reduces response
fluctuations. However, there is great interest in the neuro-
protective potential of rasagiline, which is currently the
objective of a large clinical study (USA Parkinson's Dis-
ease Group). Rasagiline may cause neuroprotection by
reducing the metabolism of dopamine, but it also pos-
sesses its own intrinsic neuroprotective properties.
Our readers may be unfamiliar with the steps 
necessary to develop a drug from the lab 
through testing, approval, sales, and 
distribution. Can you briefly summarize the 
process?
Following initial preclinical studies showing potential
activity against disease, new drugs are submitted to
exhaustive toxicity testing, including long-term adminis-
tration to several animal species, and studies in pregnant
animals. During this period, the preclinical pharmacology
studies are also broadened. If all is OK from toxicology,
one goes into stage 1 clinical testing in human volunteers
to detect any human-selective toxicity, then phase 2 in
patients (determination of active dose and maximum-tol-
erated dose), and full phase 3 study using double-blind
design whenever possible. The nail-biting period is while
one waits for the results from phase 3, i.e., opening the
codes and arranging the data for active and placebo (or
comparison drug) groups, since this is the final, objective
test of efficacy in humans. If successful, all the data are
submitted to the licensing authorities for New Drug
Application (NDA).
What obstacles have you and your colleagues 
overcome to develop rasagiline as a commercial 
drug?
Our preclinical studies, for early detection of activity, were
carried out in our university labs and in one or two other
related institutions. In the case of rasagiline, full clinical
development was carried out by Teva, Israel Pharmaceuti-
cal Industries Ltd. The fact is that, even if you have proved
a drug to be effective clinically, there is still much effort to
be invested in order for it to be accepted on the large scale
by the medical practitioners around the world. This
requires much publicity and marketing, in which medical
specialists are invited to join studies with the new drug
and to present their data at congresses to ensure that the
major clinical centers are positive about the new drug's
advantages. The "coming-out party" for rasagiline was at
the International Parkinson's Disease Congress in Berlin
(2005), and it was a tremendous experience for me to see
the rasagiline booth at the commercial exhibition there.
Our rasagiline story also appeared at the excellent exhibi-
tion on advances in Parkinson's disease at the congress.
How would you characterize the current 
paradigms for anti-Parkinson drug discovery?
The major problem in this area, as in most others, is in the
choice of the disease model in animals. Parkinson's dis-
ease develops over the course of several years, and most
patients suffer from the idiopathic disease, for which the
cause is unknown. One can reproduce disease symptoms
by injecting neurotoxins, but again, the human disease is
not caused this way. As a result, the animal models are
most useful for studying new ways to reduce symptoms,
but are poor predictors of disease-modifying agents.
What advances do you envision for anti-
Parkinson drug discovery in the coming years?
A number of genes whose mutated or overexpressed prod-
ucts cause the genetic forms of the disease have been
detected. Although most patients do not suffer fromPublish with BioMed Central    and   every 
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hereditary forms of the disease, study of the causes of
inherited parkinsonism is providing clues to the general
pathophysiology of the disease. Increasingly, genotyping
will be able to predict the at-risk subjects. There will also
be advances in early detection, probably by a combina-
tion of advanced imaging techniques and genotyping.
Early detection is a major problem in Parkinson's disease,
since by the time neurological diagnosis is made, more
than 50 percent of the substantia nigra neurons have been
lost.
What suggestions for further research would 
you make?
Almost certainly, Parkinson's disease is caused by a multi-
valent genetic combination, which may even interact with
environmental factors. As a result, it will take a long time
before the causative factors are established, and even then,
prevention or elimination of this disease may not be pos-
sible. Treatments must therefore be further improved, and
I believe that cell transplantation therapies will develop in
many interesting ways.
Do you have anything else to add or share?
I feel truly lucky to have been part of this new drug discov-
ery, but there are many other discoveries to come, so keep
up the hard work, since there is a good chance to be asso-
ciated with a major advance, as long as you concentrate on
the best quality research.
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